HLS Therapeutics Inc (FRA:74D)
€ 2.38 0.08 (3.48%) Market Cap: 78.06 Mil Enterprise Value: 126.68 Mil PE Ratio: 0 PB Ratio: 1.08 GF Score: 66/100

HLS Therapeutics Inc at Stifel Virtual Healthcare Conference Transcript

Nov 17, 2020 / 07:40PM GMT
Justin Keywood;Gilbert Godin
Stifel Nicolaus Canada Inc., Research Division - Director of Equity Research;HLS

Good afternoon, everyone, and thank you for joining our fireside chat with HLS Therapeutics. I'm Justin Keywood, a health care analyst at Stifel, and I'll be moderating the chat.

We're going to start with a brief introduction to management and the company. And then we'll just jump right into the discussion and Q&A. For those of you online, you do have the ability to ask questions throughout the 30-minute presentation here, and we'll try to fit in as many as we can.

But as you can see, the slide that we have up, HLS, it's about a $500 million market cap company, specialty health care business in the CNS and cardiovascular space. From HLS, joining us today, we have the Chief Executive Officer and Co-Founder, Gilbert Godin; and Chief Financial Officer, Tim Hendrickson. Thank you, gentlemen, for both joining and congratulations on all the recent success.

And I'll turn it over to Gilbert for a brief overview of the business. Thank you.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot